![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 16 of 16. This is the beginning of the thread.
Posted by ihatedrugs on October 25, 2011, at 0:18:40
One can only hope.
Amitifadine, A Next-Generation Antidepressant for Major Depressive Disorder
Posted by huxley on October 25, 2011, at 2:42:06
In reply to Amitifadine, A Next-Generation Antidepressant for, posted by ihatedrugs on October 25, 2011, at 0:18:40
Can't believe a word they say.
Posted by ihatedrugs on October 25, 2011, at 3:04:39
In reply to Re: Amitifadine, A Next-Generation Antidepressant for, posted by huxley on October 25, 2011, at 2:42:06
When Pandora opened the jar, all its contents except for one item were released into the world. The item was Hope and I'm holding on to it.
Posted by SLS on October 25, 2011, at 5:21:50
In reply to Re: Amitifadine, A Next-Generation Antidepressant for, posted by huxley on October 25, 2011, at 2:42:06
Hi.
> Can't believe a word they say.
I can think of only a few antidepressant drugs that turned out to be relative duds: trazodone, maprotiline, moclobemide, and reboxetine. Although these drugs won't get as many people well as Effexor, there are some people for whom they are lifesavers. A small percentage of people will respond well to them while not responding to any other drug. I feel that this is justification enough for them to remain available.
I look forward to seeing a triple reuptake inhibitor come to market. I once responded favorably to a drug called Merital (nomifensine). Like the new investigational drug described here, it blocked the reuptake of NE and DA. Certain people might be DAT inhibitor responders. Unfortunately, Merital proved to be liable to precipitate hemolytic anemia, and a few deaths were reported. Merital was withdrawn from the market worldwide after less than a year. There are people who have posted here for whom Merital was the only drug to bring them to remission.
For every new antidepressant drug that becomes available, a certain percentage of previously TRD cases will get well.
Personally, I think current investigational protocols suck. They let in too many people with mild and moderate depression that I doubt are cases of MDD. In my view, that's why these investigations produce high placebo response rates compared to active drug. When followed longitudinally, these placebo responders relapse early and in greater numbers than drug responders. You almost never here of this, though. Frederick Quitkin studied this phenomenon extensively.
- Scott
Posted by Phillipa on October 25, 2011, at 9:34:19
In reply to Re: Amitifadine, A Next-Generation Antidepressant for » huxley, posted by SLS on October 25, 2011, at 5:21:50
So I guess the key is MDD and not mild or moderate depression. But what are the definition of those as even though some go on Disability as can no longer work meds still don't seem to work unless it's the very first one? So confusing at times. Phillipa
Posted by floatingbridge on October 25, 2011, at 12:22:24
In reply to Re: Amitifadine, A Next-Generation Antidepressant for » huxley, posted by ihatedrugs on October 25, 2011, at 3:04:39
> When Pandora opened the jar, all its contents except for one item were released into the world. The item was Hope and I'm holding on to it.
>
>I love this.
Posted by ihatedrugs on October 25, 2011, at 13:40:28
In reply to Re: Amitifadine, A Next-Generation Antidepressant for » ihatedrugs, posted by floatingbridge on October 25, 2011, at 12:22:24
Hi FB,
Glad you liked it.
How have you been feeling?
ihatedrugs
Posted by floatingbridge on October 25, 2011, at 14:35:35
In reply to Re: Amitifadine, A Next-Generation Antidepressant for » floatingbridge, posted by ihatedrugs on October 25, 2011, at 13:40:28
Not so good, ihd. The fibro thing is demoralizing. My psych meds are working well enough, but they cannot do all I wanted them to do, like address fatigue. And they only help a little with pain. I'd like to find a doctor to work with, even if s/he didn't have answers.
It's good to see you. How have you been doing?
Posted by ihatedrugs on October 26, 2011, at 3:57:19
In reply to Re: Amitifadine, A Next-Generation Antidepressant for » ihatedrugs, posted by floatingbridge on October 25, 2011, at 14:35:35
I've been up and down. It's so hard to find the right combination of meds. I don't have as much trouble with the fibro/fatigue anymore. A combination of Vyvanse, Wellbutrin, Lyrica seem to do the trick. My problem is unrelenting insomnia and unwavering depression. I tried ECT but after the first treatment couldn't handle it anymore...not a pleasant experience. So I'm just trying to survive like everyone else in this board. Hoping for some miracle. Hope you feel better!
Posted by floatingbridge on October 26, 2011, at 9:51:48
In reply to Re: Amitifadine, A Next-Generation Antidepressant for » floatingbridge, posted by ihatedrugs on October 26, 2011, at 3:57:19
The best I can do for insomnia is gabapentin to lengthen my sleep and tenazepam. Other medications stopped working.
I currently on Emsam as my antidepressant and am finding it limits my pain/fatigue options. No amitriptilyne or stimulant. (I do not do well on Provigil.)
I am sorry ihd that depression has been unrelenting. I wish you the very best with this. I imagine you read the threads. There is one on suboxone and TRD.
Posted by roversreturn on October 27, 2011, at 20:53:22
In reply to Amitifadine, A Next-Generation Antidepressant for, posted by ihatedrugs on October 25, 2011, at 0:18:40
> One can only hope.
>
>
> Amitifadine, A Next-Generation Antidepressant for Major Depressive Disorder
>
> http://euthymics.com/our-programs/mdd-and-eb-1010/If you look at the study, tc-5214 could be the one for TRD, its a nicotinic receptor antagonist and should make it to market before amitifadine, its in phase 3 at the moment....fingers crossed!!!
Rover
Posted by Chairman_MAO on October 31, 2011, at 21:15:00
In reply to Re: Amitifadine, A Next-Generation Antidepressant for, posted by Phillipa on October 25, 2011, at 9:34:19
> So I guess the key is MDD and not mild or moderate depression. But what are the definition of those as even though some go on Disability as can no longer work meds still don't seem to work unless it's the very first one? So confusing at times. Phillipa
Someday, maybe they'll let us have a drug with a 1:1:1 ratio. Anytime that happens, they find some reason to remove it from the market.
Posted by sigismund on November 1, 2011, at 1:29:07
In reply to Re: Amitifadine, A Next-Generation Antidepressant for » Phillipa, posted by Chairman_MAO on October 31, 2011, at 21:15:00
There will be 100 reasons to remove it from the market. (I gather these ratios do not include the opiate or GABA receptors?) People are now abusing Seroquel yet before 1968 heroin was available OTC here in unit doses for hangovers. Clearly we need closer supervision.
Posted by Chairman_MAO on November 3, 2011, at 19:42:51
In reply to Re: Amitifadine, A Next-Generation Antidepressant for » Chairman_MAO, posted by sigismund on November 1, 2011, at 1:29:07
> There will be 100 reasons to remove it from the market. (I gather these ratios do not include the opiate or GABA receptors?) People are now abusing Seroquel yet before 1968 heroin was available OTC here in unit doses for hangovers. Clearly we need closer supervision.
Clearly we need a rational drug policy; the combined death toll and other social costs from alcohol and tobacco eclipses that of all other illicit drugs combined many times over.
What do you mean by "those ratios do not include opiate [sic.] or GABA receptors"?
Posted by jhj on November 8, 2011, at 6:34:04
In reply to TC-5214, posted by roversreturn on October 27, 2011, at 20:53:22
Posted by roversreturn on November 10, 2011, at 20:45:32
In reply to Re: TC-5214, posted by jhj on November 8, 2011, at 6:34:04
I know, egg on face, makes a mockery of this entire study then!!!
Rover
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.